Contraceptive Pill Blood Test: What to Monitor

Approximately 3.1 million women in the UK use the combined oral contraceptive pill, making it the most popular form of hormonal contraception. When you're prescribed the pill, your GP checks your blood pressure, asks about family history of blood clots and migraines with aura, and then hands you a prescription. What they almost never do is a blood test — before starting, during use, or at any point afterwards.

This is a significant gap in monitoring. The combined pill has measurable effects on liver function, lipid metabolism, hormone-binding proteins, and micronutrient levels. Most of these changes are clinically benign, but some aren't — and the only way to distinguish between them is to measure. Here's what to test and why.

Blood Clot Risk: What the Pill Actually Does

The combined pill increases the risk of venous thromboembolism (blood clots) by 2–4 times baseline risk. For a healthy young woman, baseline risk is approximately 2 per 10,000 woman-years — rising to 5–12 per 10,000 on the combined pill. This is still a low absolute risk, but it's not negligible, and certain factors multiply it further: obesity, smoking, immobility, family history of thrombophilia (factor V Leiden, prothrombin gene mutation), and age above 35.

Blood tests cannot predict a blood clot before it happens, but they can identify risk factors that might change the risk-benefit calculation. Thrombophilia screening (factor V Leiden, prothrombin 20210 mutation, antithrombin, protein C, protein S) is not routine but should be considered if you have a first-degree relative who had a clot before age 45.

What blood tests can do is monitor the metabolic consequences of the pill — liver stress, lipid changes, and hormonal shifts — that are actionable and modifiable.

Liver Function: First-Pass Metabolism

Oral contraceptives undergo first-pass metabolism in the liver before reaching the systemic circulation. The synthetic oestrogen (ethinylestradiol) and progestogen are processed by hepatic cytochrome P450 enzymes, placing a measurable load on liver function.

In most women, liver enzymes remain within normal range. However, a minority experience elevated ALT and/or AST, particularly in the first 3–6 months. Women with pre-existing liver conditions, those who drink alcohol regularly, or those taking other hepatically metabolised medications (paracetamol, certain antibiotics, antifungals) are at higher risk.

GGT is a particularly useful marker for pill users — it reflects both the hepatic metabolic burden and any alcohol-related liver stress that might compound the pill's effects. Bilirubin should also be monitored, as the combined pill can unmask Gilbert syndrome (a benign genetic condition affecting bilirubin metabolism that's present in 5–10% of the population) or, in rare cases, contribute to cholestatic jaundice.

Lipid Panel: Triglycerides Are the Key Marker

The combined pill has a complex effect on lipid metabolism. Ethinylestradiol raises HDL cholesterol (generally positive), raises triglycerides (negative), and has variable effects on LDL depending on the progestogen component. Second-generation progestogens (levonorgestrel) tend to raise LDL, while third-generation (desogestrel, gestodene) and anti-androgenic progestogens (drospirenone) tend to lower it or have a neutral effect.

The triglyceride elevation is the most clinically significant change. The combined pill raises triglycerides by 30–75% in most women. For someone with normal baseline triglycerides (below 1.7 mmol/L), this increase is usually tolerable. For someone with borderline-high triglycerides (1.7–2.3 mmol/L) before starting the pill, it can push them into a range associated with metabolic syndrome and pancreatitis risk.

A lipid panel before starting the pill, and again at 3–6 months, identifies women in whom the triglyceride elevation is excessive. Switching to a different progestogen, using a lower oestrogen dose, or considering a progestogen-only alternative may be appropriate.

SHBG: The Hidden Hormone Impact

Sex hormone-binding globulin (SHBG) is dramatically affected by the combined pill — often rising 2–4 times above baseline. This is arguably the most underappreciated metabolic consequence of combined oral contraception.

SHBG binds testosterone, making it unavailable to tissues. When SHBG doubles or triples, free testosterone plummets — even though total testosterone may remain technically within range. The clinical consequences can include reduced libido, vaginal dryness, fatigue, and reduced sense of wellbeing. These symptoms are frequently attributed to "psychological" causes or dismissed as normal, when in reality they have a clear biochemical explanation.

What makes this particularly significant is that SHBG can remain elevated for 6–12 months after stopping the pill. Women who discontinue the pill due to low libido may not see improvement for months, leading them to conclude the pill wasn't the cause when it actually was.

Testing SHBG and free testosterone (calculated from total testosterone, SHBG, and albumin) while on the pill provides a baseline. If SHBG is above 100 nmol/L and symptoms of androgen deficiency are present, discussing alternative contraception with your prescriber is warranted.

B12, Folate, and Micronutrient Depletion

The combined pill has been shown to reduce serum levels of several micronutrients. The evidence is strongest for:

• Vitamin B6 — depleted by the oestrogen component; associated with mood disturbance
• Vitamin B12 — reduced absorption; especially relevant for vegetarian/vegan women
• Folate — reduced serum levels; critically important if the pill is stopped for pregnancy
• Magnesium — increased urinary excretion; may contribute to headaches and cramps
• Zinc — reduced serum levels; important for immune function and wound healing

The folate depletion is particularly concerning from a public health perspective. Approximately 45% of pregnancies in the UK are unplanned. A woman who stops the pill and conceives quickly may have suboptimal folate levels precisely when neural tube closure is occurring (weeks 3–4 of pregnancy). This is one reason why some countries have considered adding folic acid to oral contraceptive formulations.

Testing B12, folate, and vitamin D while on the pill — particularly if you've been taking it for several years — establishes whether supplementation is needed.

Vitamin D and Thyroid Function

Vitamin D metabolism is affected by the pill through its effects on vitamin D-binding protein. The clinical significance is debated, but some studies suggest that pill users have altered vitamin D status that may not be fully captured by standard 25-hydroxyvitamin D testing. Testing vitamin D annually is sensible regardless.

The combined pill increases thyroid-binding globulin (TBG), which raises total T4 levels without affecting free T4 or TSH. This means that total T4 is unreliable in pill users — only free T4 and TSH should be used for thyroid assessment. If thyroid symptoms are present while on the pill, ensure your test includes free T4 and TSH rather than relying on total T4 alone.

What About the Progestogen-Only Pill?

The progestogen-only pill (POP, or mini-pill) has a different metabolic profile. It doesn't contain oestrogen, so it doesn't increase blood clot risk, doesn't significantly raise triglycerides, and has less effect on SHBG and liver function. However, it can still affect mood through progesterone receptor-mediated mechanisms, and micronutrient monitoring is still advisable for long-term users.

The monitoring recommendations in this article are primarily for the combined pill. POP users should still consider baseline and periodic testing, but the urgency is less.

When to Test

Ideally, test before starting the pill (baseline lipids, liver function, SHBG, thyroid, and micronutrients), then again at 3–6 months (to assess the metabolic impact), and annually thereafter. If you've been on the pill for years without any blood testing, a single comprehensive panel now provides a snapshot of current status — better late than never.

If you're planning to stop the pill for pregnancy, test folate, B12, iron, and vitamin D at least 3 months before discontinuation to allow time for supplementation if needed.

Recommended Blood Tests

The Female Hormones 7 biomarker test (£95) covers SHBG, testosterone, free testosterone calculation, LH, FSH, and oestradiol — providing the hormonal assessment needed to evaluate the pill's impact on androgen status and identify SHBG-related side effects.

For comprehensive monitoring including liver function, lipids, thyroid, B12, folate, vitamin D, and iron alongside the basic metabolic markers, the Core Health 45 biomarker test (£120) covers all the key markers discussed in this article in a single panel.

Your GP monitors blood pressure on the pill. Nobody monitors the rest. A blood test once a year fills that gap and ensures you're making informed decisions about your contraception based on data rather than assumption.